SCHEMBL5562015

SCHEMBL5562015

CCCCCCCCC=CCCCCCCCC[C@@]1(n2cnc3c(N)ncnc32)O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.46
ADORA3 P0DMS8 4/20 0.46
EHMT1 Q9H9B1 1/20 0.44
GMPS P49915 1/20 0.44
PI4KA P42356 2/20 0.42
PI4K2B Q8TCG2 2/20 0.42
PI4K2A Q9BTU6 2/20 0.42
PI4KB Q9UBF8 2/20 0.42
SLC28A1 O00337 2/20 0.42
ADORA1 P30542 2/20 0.42
DPP4 P27487 1/20 0.42
MEN1 O00255 1/20 0.42
MAP3K7 O43318 1/20 0.42
SLC28A2 O43868 1/20 0.42
GAPDH P04406 1/20 0.42
MAPK1 P28482 1/20 0.42
ADORA2B P29275 1/20 0.42
STAT6 P42226 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10865960 0.94 ADORA3 (0.48) ADORA2AADORA3EHMT1GMPSPI4KA
SCHEMBL1920532 0.94 ADORA3 (0.48) ADORA2AADORA3EHMT1GMPSPI4KA
SCHEMBL9231750 0.94 ADORA3 (0.49) ADORA2AADORA3EHMT1GMPSPI4KA
SCHEMBL29509039 0.91 ADORA3 (0.50) ADORA2AADORA3EHMT1GMPSPI4KA
Phosphoric Acid SCHEMBL15210131 0.89 EHMT1 (0.46) ADORA2AADORA3EHMT1GMPSPI4KA
SCHEMBL30629421 0.89 ADORA3 (0.44) ADORA2AADORA3GMPSPI4KAPI4K2B
SCHEMBL28205583 0.87 ADORA3 (0.50) ADORA2AADORA3GMPSPI4KAPI4K2B
SCHEMBL2534138 0.87 ADORA3 (0.52) ADORA2AADORA3EHMT1GMPSPI4KA
SCHEMBL25349321 0.86 ADORA3 (0.49) ADORA2AADORA3GMPSPI4KAPI4K2B
SCHEMBL4884773 0.85 EHMT1 (0.47) ADORA2AADORA3EHMT1GMPSPI4KA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070160554-A1 Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same COGNIS IP MANAGEMENT GMBH (DE) 2007-07-12 US claimed
EP-1680435-A1 ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES Cognis IP Management GmbH (DE) 2006-07-19 EP claimed
WO-2005049633-A1 ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES COGNIS IP MANAGEMENT GMBH (DE) 2005-06-02 WO claimed
US-20070160554-A1 Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same COGNIS IP MANAGEMENT GMBH (DE) 2007-07-12 US disclosed
EP-1680435-A1 ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES Cognis IP Management GmbH (DE) 2006-07-19 EP disclosed
WO-2005049633-A1 ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES COGNIS IP MANAGEMENT GMBH (DE) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070160554-A1 Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same RNASEL, RNASEH1, DUT ADORA2A 317/4885ADORA3 299/4885EHMT1 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.